- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03145116
Clinical Safety and Efficacy of CT ASPHINA 509 Lenses (UVEA509)
July 17, 2018 updated by: Carl Zeiss Meditec AG
Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses - Retro Prospective Study
Clinical safety and efficacy of CT ASPHINA 509 IOLs after implantation
Study Overview
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ahaus, Germany, 12593
- Augenklinink
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patient informed of the consequences and constraints of the protocol and who has given his/her written informed consent;
- Patients of any gender
- Assured follow-up examinations
- Biometry measurement preferably compatible with the IOLMaster evaluation;
- IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in one eye with at least 12 months follow up at the time of the postop visit
- Patients who had uncomplicated (no peroperative complication) agedrelated cataract surgery in a healthy eye (beside clinically significant cataract)
Exclusion Criteria:
• BCVA not available preoperatively or better than 0.3 logMAR pre-op
- Patients unable to meet the limitations of the protocol or likely of noncooperation during the trial
- Patients whose freedom is impaired by administrative or legal order
- Concurrent participation in another drug or device investigation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 509
|
Intraocular lens
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity
Time Frame: 12 to 18 months after surgery
|
Monocular best corrected distance visual acuity
|
12 to 18 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2017
Primary Completion (Actual)
February 5, 2018
Study Completion (Actual)
February 5, 2018
Study Registration Dates
First Submitted
May 5, 2017
First Submitted That Met QC Criteria
May 5, 2017
First Posted (Actual)
May 9, 2017
Study Record Updates
Last Update Posted (Actual)
July 18, 2018
Last Update Submitted That Met QC Criteria
July 17, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASPHINA 509-BER-401-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on CT ASPHINA 509
-
Carl Zeiss Meditec AGCompleted
-
Centre Hospitalier Régional Metz-ThionvilleRecruitingCataract | Intraocular Lens ImplantFrance
-
University of PlymouthCarl Zeiss Meditec AG; University Hospital Plymouth NHS Trust; Glasgow Caledonian... and other collaboratorsRecruitingCataract Bilateral | Astigmatism BilateralUnited Kingdom
-
Aragon Pharmaceuticals, Inc.Active, not recruiting
-
Aragon Pharmaceuticals, Inc.Completed
-
Sangamo TherapeuticsCompletedAmyotrophic Lateral SclerosisUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedRheumatoid ArthritisUnited States, Denmark, Estonia, Lithuania, Netherlands, South Africa
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedRheumatoid ArthritisPoland, Belgium, Romania, Serbia, United States, Puerto Rico, Germany, Hungary, Russian Federation, Croatia
-
Sangamo TherapeuticsJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic PolyneuropathyUnited States, Mexico